TD Cowen Reiterates Buy Rating on Acrivon Therapeutics Inc (ACRV)

TD Cowen analyst Marc Frahm reiterated a Buy rating on Acrivon Therapeutics Inc (NASDAQ: ACRV).

The analyst commented, "Acrivon presented updated ACR-368's monotherapy and LDG combo cohorts in endometrial cancer. Monotherapy is maintaining a 46-63% ORR in BM+ patients which compares very favorably to 2L salvage chemotherapy (10% ORR or less). Enrollment continues and if maintained this efficacy signal would represent both a significant outcome for endometrial patients and validation of the AP3 platform."

For an analyst ratings summary and ratings history on Acrivon Therapeutics Inc click here. For more ratings news on Acrivon Therapeutics Inc click here.

Shares of Acrivon Therapeutics Inc closed at $8.91 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton